Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

The present study aimed to evaluate the side-effects and efficacy of thalidomide in combination with an anthracycline-containing chemotherapy regimen in previously untreated myeloma patients. Thalidomide (400 mg/d) was combined with bolus injections of vincristine and epirubicin and oral dexamethaso...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Hoiczyk, M, Flasshove, M, Hense, J, Bojko, P, Metz, K, Moritz, T, Seeber, S, Nowrousian, MR
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2005

Eitemau Tebyg

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
gan: Schütt, P, et al.
Cyhoeddwyd: (2005)

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
gan: Schütt, P, et al.
Cyhoeddwyd: (2005)

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
gan: Schütt, P, et al.
Cyhoeddwyd: (2006)

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
gan: Nowrousian, MR, et al.
Cyhoeddwyd: (2005)

The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
gan: Schütt, P, et al.
Cyhoeddwyd: (2008)

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
gan: Rebmann, V, et al.
Cyhoeddwyd: (2007)

Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
gan: Juan M. Cano-Calderón, et al.
Cyhoeddwyd: (2025-01-01)

High dose Simvastatin does not reverse resistance to Vincristine, Adriamycin, and Dexamethasone (VAD) in Myeloma
gan: E. van der Spek, et al.
Cyhoeddwyd: (2007-12-01)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
gan: V. Del Fabro, et al.
Cyhoeddwyd: (2023-05-01)

Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone
gan: Di Wang, et al.
Cyhoeddwyd: (2021-01-01)

Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India
gan: Nithin Sashidharan, et al.
Cyhoeddwyd: (2015-05-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
gan: Edvan De Queiroz Crusoe, et al.
Cyhoeddwyd: (2020-04-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
gan: Yin-Che Wang, et al.
Cyhoeddwyd: (2025-12-01)

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
gan: Jew Win Kuan, et al.
Cyhoeddwyd: (2022-01-01)

The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step‐up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study
gan: Po‐Wei Liao, et al.
Cyhoeddwyd: (2024-05-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
gan: Taleb Azarm, et al.
Cyhoeddwyd: (2012-01-01)

Altered Regional Brain Glucose Metabolism in Diffuse Large B-Cell Lymphoma Patients Treated With Cyclophosphamide, Epirubicin, Vincristine, and Prednisone: An Fluorodeoxyglucose Positron Emission Tomography Study of 205 Cases
gan: Yuxiao Hu, et al.
Cyhoeddwyd: (2022-06-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
gan: Laura Rosiñol, et al.
Cyhoeddwyd: (2023-11-01)

Preexposure of MCF-7 breast cancer cell line to dexamethasone alters the cytotoxic effect of paclitaxel but not 5-fluorouracil or epirubicin chemotherapy
gan: Buxant F, et al.
Cyhoeddwyd: (2017-03-01)

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
gan: Martin Kropff, et al.
Cyhoeddwyd: (2012-05-01)

Restarting Thalidomide-Dexamethasone Regimen in a Post-Abortive Female with Multiple Myeloma: Effective Clinical Response Possible
gan: Suhailur Rehman, et al.
Cyhoeddwyd: (2017-07-01)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
gan: Karthik Ramasamy, et al.
Cyhoeddwyd: (2022-11-01)

Thalidomide in treatment of connective diseases and vasculities
gan: D. Ribatti, et al.
Cyhoeddwyd: (2011-09-01)

Nanoparticle Effect on Interaction of Epirubicin with DNA
gan: Leyla Karadurmus, et al.
Cyhoeddwyd: (2017-11-01)

P1067: PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS
gan: J.-N. Wang, et al.
Cyhoeddwyd: (2022-06-01)

New therapies for heart failure: is thalidomide the answer?
gan: Davey, P, et al.
Cyhoeddwyd: (2000)

Thalidomide, the story goes on
gan: Esther Papaseit, et al.
Cyhoeddwyd: (2023-06-01)

Treatment of Aphthae with Thalidomide
gan: Mahmoud Farshchian
Cyhoeddwyd: (1994-03-01)

Thalidomide in dermatology: Revisited
gan: Iffat Hassan, et al.
Cyhoeddwyd: (2015-01-01)

Gammel Testamente ved Det Teologiske Fakultet ved Aarhus Universitet
gan: Hans J. Lundager Jensen
Cyhoeddwyd: (2009-09-01)

Genoptagelse ved hjælp af proformer ved simultantolkning fra tysk
gan: Friedel Dubslaff
Cyhoeddwyd: (2017-02-01)

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study
gan: Patrice Chevallier, et al.
Cyhoeddwyd: (2015-04-01)

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
gan: Henk M. Lokhorst, et al.
Cyhoeddwyd: (2008-01-01)

Reaksjonene ved promillekjøring
gan: R. N. Torgersen
Cyhoeddwyd: (1984-05-01)

Straffutmålingsnivået ved voldsforbrytelser
gan: Georg Fr. Rieber-Mohn
Cyhoeddwyd: (1988-08-01)

Styring ved straff
gan: Nils Christie
Cyhoeddwyd: (2000-09-01)

Epidemiologi ved korsryggsmerter
gan: Dag Magnar Soldal
Cyhoeddwyd: (2008-01-01)

Studieplanlægning ved lægeuddannelserne
gan: Anne Mette Mørcke, et al.
Cyhoeddwyd: (2010-03-01)

Gaveøkonomi ved Nasjonalmuseet
gan: Ane Moe
Cyhoeddwyd: (2016-01-01)

Polyphosphazene-Based Nanocarriers for the Release of Camptothecin and Epirubicin
gan: Javier Pérez Quiñones, et al.
Cyhoeddwyd: (2022-01-01)